Aditxt's Adivir, Inc., Agreed To Acquire All Outstanding Class A Common Shares Of Appili Under The Third Amending Agreement; Transaction Is Conditional Upon Aditxt Raising At Least $20M In Financing Before Closing
Aditxt's Adivir, Inc., Agreed To Acquire All Outstanding Class A Common Shares Of Appili Under The Third Amending Agreement; Transaction Is Conditional Upon Aditxt Raising At Least $20M In Financing Before Closing
Aditxt, Inc. ("Aditxt" or "the Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it had entered into a third amending agreement with Appili Therapeutics, Inc. (TSX:APLI, OTC:APLIF) ("Appili"), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential bioterrorism threats.
Aditxt, Inc. ("Aditxt"或"公司") (NASDAQ:ADTX)，一家致力於發現、開發和部署有前景的健康創新的創新平台，今天宣佈與Appili Therapeutics, Inc. (TSX:APLI，OTC:APLIF) ("Appili")簽訂了第三份修訂協議，Appili是一家專注於開發創新治療方法和疫苗以應對一些具有挑戰性的傳染性疾病和潛在生物恐怖主義威脅的生物製藥公司。
Under the terms of the Arrangement Agreement announced on April 2, 2024, Aditxt, through its wholly-owned subsidiary Adivir, Inc., agreed to acquire all outstanding Class A common shares of Appili. Under the third amending agreement, the Arrangement Agreement was amended to, inter alia: (i) change the Outside Date (as defined in the Arrangement Agreement) from September 30, 2024 to November 19, 2024; (ii) require Appili to convene an annual and special shareholder's meeting of Appili to consider, among other things, the Continuance (as defined below) as promptly as practicable; (iii) change the deadline to convene a special shareholders' meeting to consider the Transaction from September 30, 2024 to November 6, 2024; (iv) change the deadline for Aditxt to complete the Financing (as defined in the Arrangement Agreement) from September 15, 2024 to October 18, 2024; and (v) have the completion of the Continuance as a condition to the completion of the Arrangement.
根據2024年4月2日宣佈的協議的條款，Aditxt通過其全資子公司Adivir, Inc.同意收購Appili的所有未上市A類普通股。根據第三份修訂協議，該協議被修訂爲：（i）將外界日期（在該協議中定義）從2024年9月30日更改爲2024年11月19日；（ii）要求Appili召集Appili的年度股東大會和特別股東大會，以儘快考慮繼續進行（如下所定義）；（iii）將召集特別股東大會考慮交易的截止日期從2024年9月30日更改爲2024年11月6日；（iv）將Aditxt完成融資（在該協議中定義）的截止日期從2024年9月15日更改爲2024年10月18日；以及（v）將繼續完成作爲完成交易的條件。
The transaction is conditional upon Aditxt raising at least US$20 million in financing before closing. In addition, completion of the transaction is subject to other customary conditions, including the receipt of all necessary court, regulatory, and stock exchange approvals. No assurance can be given that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close.
交易的條件是Aditxt在交易完成前至少籌集2000萬美元的融資。此外，交易完成還需要滿足其他常規條件，包括獲得所有必要的法院、監管和股票交易所的批准。不能保證所有的交易完成條件都能獲得或滿足，也不能保證最終能夠完成交易。
